Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talimogene Laherparepvec with Chemoradiation in Head and Neck Cancer
NCT01161498Phase 3Terminated
- Sponsor
- BioVex Group, Inc.
- Start
- Feb 2011
- Primary completion
- Oct 2011
- Modality
- Oncolytic Viruses
- Countries
- 2
01
Overview
A Phase 3 trial of talimogene laherparepvec in squamous cell carcinoma of the head and neck (HNSCC), sponsored by BioVex Group, Inc.. Started Feb 2011; status: terminated.
02
Drugs
talimogene laherparepvec
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01161498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01161498.